Peraso

Peraso Enables Next Generation Mobiles. Peraso’s 60 GHz ICs unlock 9 GHz of unlicensed spectrum in the 57-66GHz band, and thus acts as an enabling technology for a variety of new applications in the mobile realm.

In the mobile infrastructure market, 60 GHz is viewed as a primary technology choice for small cell backhaul. With features such as high bandwidth, narrow beamwidth and low latency, 60 GHz provides carriers with a viable, cost effective option to traditional backhaul methods such as fiber or microwave.

In mobile devices such as smartphones and tablets, 60 GHz provides a wireless alternative to existing wired standards like USB3.0 or HDMI. Peraso’s WiGig 60 GHz chipsets address this market with industry leading energy efficiency, a compact form factor, and sub-frame glass to glass latency.

FOTA

FOTA : Dr. Tony Carusone at the Univ of Toronto has developed patent-pending breakthrough technology that both efficiently and affordably performs optoelectronic conversion for high-speed data signals within a tiny footprint.

Sustained data transfer rates equivalent to three parallel streams of high-definition video have been demonstrated in prototype components. Devices and customer evaluation boards are currently available for testing by qualified partners.

Dr. Carusone’s technology enables dramatic reductions in both cost and size while enabling significant performance improvements.

http://fotatech.com/

Read Introduction by MaRS: http://marsinnovation.com/company/fota-technologies/

e-Therapeutics

e-Therapeutics completes £40m placing e-Therapeutics plc (AIM: ETX, http://www.etherapeutics.co.uk), a spinout from Newcastle University, is a drug discovery and development company which is pioneering network pharmacology, a new approach to the discovery of medicines.
On 1st March, e-Therapeutics announced the completion of two share placings that raised £40 million in new equity (approximately £39 million net). The new shares were priced at 32p, a premium of 4% to the price on previous dealing day. Following the funding, the company has net cash and liquid resources of approximately £48 million, which together with expected receipts from R&D tax credits and interest, are intended to support all of its currently planned discovery and development activities into 2017, by which time an outlicensing deal for the company’s lead cancer drug ETS2101 should be in place.
As a result of the latest investment, Invesco Asset Management now holds 45.9% of the company’s shares, together with Henderson Global Investors (12.1%), Octopus Group (6.3%), Newcastle University (4.9%), and founder Professor Malcolm Young (14.9%), in all accounting for 84.1% of the company.

PathXL

PathXL (www.pathxl.com), is the winner of 2012 Deloitte Technology Fast 50 – a spin-out from Queen’s University Belfast established in 2005, is a pioneer in the use of web-based solutions for digital pathology, mainly in regard to cancer. Its PathXL™ Manager product provides a web-based platform to enable digital pathology users across all fields to manage, view and collaborate around virtual slides easily and efficiently. In addition, PathXL provides a range of applications and workflows to deliver specific solutions to pathologists, scientists and students in education, research, clinical and biobanking settings. PathXL also provides a full range of supporting services, including scanning, hosting, image analysis and consultancy.

MiDaz Laser

Midaz Lasers Ltd

On 31st Oct 2012 Coherent Inc announced its acquisition of MiDAZ Lasers, a spinout from Imperial College London started in 2006, at the same time acquiring Innolight Innovative Laser and Systemtechnik GmbH. Coherent believes that together these companies provide core technology building blocks for an emerging class of commercial, low cost, subnanosecond pulsed lasers for micro-electronics manufacturing. The patented MiDAZ technology enables simple amplifiers to be incorporated in a broad range of laser products delivering power scaling and long lasting performance in electrically efficient designs.
Innolight manufactures low power, short pulse lasers for industrial applications like silicon processing, and ultra-stable continuous wave lasers used in demanding scientific applications like atom trapping.

Founded in 1966, Coherent Inc (Nasdaq:COHR http://www.Coherent.com) provides photonics based solutions to the commercial and scientific research markets.

MIDAZ ltd, Bessemer Bldg, Prince Consort Rd
London SW7 2AZ, United Kingdom

URL:www.midaz.co.uk
Year Founded:2006

CYP Design

De Montfort University (DMU) has joined forces with Ithaka Life Sciences to market new technology invented by Prof Bob Chaudhuri, which will provide new products and services based on a set of proteins, named cytochrome P450s (CYPs). CYPs are found in the human liver and are mostly responsible for the metabolism of drugs in people. These proteins are commercially available for use by firms involved in the discovery of new drugs, but are inconvenient to use as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.
The new technology from DMU allows CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain. This will reduce the cost and make their use in testing new drugs much quicker and easier.
DMU and Ithaka have established a new company called CYP Design Ltd (CDL). DMU has licensed the new technology to CDL which will now bring the new products to market. Ithaka has worked closely with Prof Chaudhuri to set up CDL and is leading the implementation of the business strategy through Dr Bill Primrose as CEO and Dr Paul Rodgers as chairman.

http://www.cyp-design.com/

KERACOL

Keracol  ‘functional, natural, sustainable cosmetics’,  is a spin-out company from the University of Leeds, producing cosmetic products for hair coloration, hair care and skin care using novel approaches to the extraction, fractionation and purification of natural active molecules in the cleanest, most energy efficient way.
The company was founded by Dr Richard Blackburn, Senior Lecturer in Coloration Technology, and Prof Christopher Rayner, Head of Organic Chemistry, at the University of Leeds. Prof Rayner previously founded C-Capture, and he and Dr Blackburn together founded DyeCat, both spinouts from Leeds.

Keracol Leeds healthcare products & services 16-Aug-11 http://www.keracol.co.uk

Impression Technologies

Impression Technologies is an aluminium forming technology business based on intellectual property developed at Imperial College London.
The world’s automotive and transport industries will have to make a step change in their use of aluminium if they are to meet into complex shapes due to its limited ductility. Current technologies cannot meet the challenges faced in producing sophisticated shapes and structures for high volume applications cost effectively.
Prof Lin of Imperial College London and Dean of the University of Birmingham have developed the Hot Form Quench (HFQ) technology, which provides a cost-competitive means of producing lightweight, complex and structured aluminium components for the automotive, aerospace and rail industries.
In the patented HFQ process, an aluminium sheet is heated above its Solution Heat Treatment temperature, formed while hot, and quenched in the press. This process allows pressings to be formed which are lighter, deeper and with tighter radii than has been possible to date. The process is quicker and more costeffective than current methods, results in superior metallurgical properties, and allows stronger and lighter structures to be formed.
Impression Technologies is headed by CEO George Adam, an experienced automotive manager with over 30 years’ experience at GKN plc and ESAB China, and chairman Mike Foster, formerly CEO of Charter International plc, which he headed for five years following a career at GKN plc and Kvaener.http://www.impressiontech.ca/

Anacail

Anacail was formed to commercialise technology developed at the Glasgow University’s School of Physics and Astronomy. The technology can rapidly and safely turn some of the oxygen inside packaged food into ozone, a very effective germicide. Plasma generated by a retractable device held briefly against the surface of plastic or glass packaging splits the bonds between oxygen molecules (O2) inside the packaging which then reform as ozone (or O3). The ozone naturally returns to its original state after just a couple of hours – more than enough time for any mould, fungi or bacteria on the packaging’s contents to be destroyed without adversely affecting its taste.
The product’s effectiveness as a germ-killer also extends food’s shelf-life by at least one extra day, and has been proven at UK labs including Campden BRI in Gloucestershire, where tests have shown an increase in shelf-life for products including bread and muffins, and a significant reduction of many pathogens in poultry including campylobacter, pseudomonas, and E.coli. The name Anacail means ‘shield’, ‘preserve’ or ‘protect’ in Gaelic.

Brainomix

Brainomix developed a software that allows expertise of a world class stroke assessment team to be accessible by any doctor in an emergency department.
Brainomix is led by managing director Dr Michalis Papadakis, along with co-founders Professor Iris Grunwald and Professor Alastair Buchan, Professor of Stroke Medicine and Head of the Medical Sciences Division at the University of Oxford.

e-ASPECTS automates the Alberta Stroke Program Early CT Score (ASPECTS) pioneered by Prof Buchan. Over the last 12 years ASPECTS has been adopted worldwide. The original ASPECTS system relies on a scoring system to assess CT (X-ray computed tomography) scans but requires a stroke expert to gauge the images. The automated e-ASPECTS encapsulates the expertise of Prof Buchan and his team in software that processes CT images. The software gives a score that can be used by any doctor to assist in deciding on an intervention where there is only a four and a half hour window for treatment from the onset of the stroke.http://www.brainomix.com/

Brainomix was set up by Isis Innovation, the technology transfer arm of the University of Oxford, and developed with the support of the National Institute for Health Research Oxford Biomedical Research Centre.